"label","name","uuid:ID","id","description","rationale","instanceType"
"","Study Design 1","794aa755-14d2-45ab-a6e0-a8647877762f","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign"
